Clinical trials: Zoledronic Acid
Postmenopausal Osteoporosis
Pravastatin Reduces Acute Phase Response of Zoledronic Acid
Acute phase response (APR) is one of the most common adverse events in osteoporosis with zoledronic acid treatment. It's reported that this reaction is related to the blockade of the mevalonate pathway, leading to isopentenyl…
- Trial name
- NCT04719481
- Testing
- Pravastatin Sodium 80 MG
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Healthy Postmenopausal Women
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
THAR2011-1 is a Phase I, single dose, open-label dose-escalation study to determine the safety, absolute bioavailability, dose proportionality, and pharmacokinetics of T121 in healthy postmenopausal women.
- Trial name
- NCT01721993
- Testing
- T121, Zoledronic acid
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Thar Pharmaceuticals, Inc
Postmenopausal Osteoporosis
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
The recommended dosing regimen of zoledronic acid in Chinese osteoporosis patients is completely in accordance with the one of 5 mg per year abroad that based on the dosing regimen in Paget's disease.
- Trial name
- NCT04719650
- Testing
- Zoledronic Acid Injection
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Breast Cancer
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in…
- Trial name
- CTIBL (NCT00712985)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Osteoporosis
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion…
- Trial name
- NCT01267279
- Testing
- Zoledronic acid
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Spokane Joint Replacement Center
Controlled Type 2 Diabetic Patients With Periodontitis
Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM
The present randomized placebo-controlled trial aims to evaluate and compare the clinical and radiographic efficacy of subgingivally delivered 0.05% zoledronate gel and 1% metformin gel as adjuncts to minimally invasive…
- Trial name
- NCT07753317
- Testing
- All participants will receive MINST
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cairo University
Osteoporosis, With or Without Treatment, Bisphosphonate Treatment
Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use
Bisphosphonates are drugs that prevent bone loss by blocking the activity of cells that normally resorb bone. The most common examples of these drugs are Boniva and Fosamax.
- Conditions
- Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ)
- Trial name
- NCT01875458
- Where
- United States
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Denosumab vs Zoledronate
Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture
Bone mineral density and function at 1 year after screw fixation with denosumab vs zoledronic acid for osteoporotic vertebral compression fractures: a parallel double-blind randomized controlled clinical trial
- Trial name
- NCT05106517
- Testing
- Denosumab, Zoledronic acid
- Where
- China
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Shenzhen People's Hospital
Breast Cancer, Osteoporosis
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00114270
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Virginia